NCT00761007 - Ibodutant for Relief of Irritable Bowel Syndrome (IRIS) | Biotech Hunter

Enrollment

554

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions

Irritable Bowel Syndrome

Interventions

DRUG

Ibodutant

Oral tablet, dose level 1 (10 mg), once daily

DRUG

Ibodutant

Oral tablet, dose level 2 (30 mg), once daily

DRUG

Ibodutant

Oral tablet, dose level 3 (60 mg), once daily

DRUG

Placebo

Oral tablet matching the three dose levels of ibodutant, once daily

Trial Locations (6)

Center for Clinical and Basic Research (CCBR), Ballerup Municipality

emovis GmbH, Berlin

"Digestive Diseases Center Gastro", Riga

"Federal State Institution Outpatient clinic #3 of President's Management Department of the Russian Federation", Moscow

Academy of Medical Science of Ukraine, Dnipropetrovsk

Synexus Midlands Clinical Research Centre, Birmingham